BAX and colorectal carcinoma: Working on three different CRC lines, Encarnação et al. (2019) also demonstrated that butyrate exerts anti-proliferative effects by inhibiting TP53 and CDKN1A activities and increasing the BAX/BCL-2 ratio [53].